Forty Seven Inc.

Biotechnology ResearchCalifornia, United States11-50 Employees

Forty Seven Inc. is a biotechnology research company focused on immuno-oncology, aiming to enhance anti-tumor efficacy and selectivity by engaging novel and complementary phagocytic pathways. Based in Menlo Park, California, the firm positions itself within the clinical-stage sector, developing therapies intended to activate macrophages in the fight against cancer. The company targets cancer patients and the research community seeking new approaches to immuno-oncology, addressing the need for more effective and selective treatment options. Forty Seven has collaborated with other industry players and has pursued partnerships to advance its clinical programs, reflecting its role as a player in the broader cancer immunotherapy landscape. The organization operates with a relatively small team, emphasizing its position as a specialized, research-driven entity within the competitive biotechnology environment. A notable development in its history includes the acquisition by Gilead Sciences, indicating integration into a larger pharmaceutical portfolio while continuing to influence its strategic direction within the field.

Sign up for free to view info

Email Format Employee directory